Pradonal

Quick links to important sections

Pradonal

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pradonal

Property Description
Active Ingredients Acetaminophen (Paracetamol) and Tramadol Hydrochloride
Form Oral Tablet
Pharmacological Class Central-acting analgesic / Opioid and Non-opioid combination
General Purpose Systemic Pain Relief
Origin Synthetic

What Type of Combination Analgesic is Pradonal?

Pradonal is a proprietary, synthetic fixed-dose combination product formulated as an oral tablet and is clinically classified as a central-acting analgesic. Its composition, which incorporates the Non-opioid analgesic Acetaminophen (Paracetamol) and the Opioid agonist Tramadol Hydrochloride, defines its identity as a medicine utilizing a dual mechanism of action. The combination of these two established agents is designed to provide comprehensive pain mitigation and is pharmacologically supported for use when less potent analgesics are insufficient.

Unlike simple single-agent medicines, Pradonal's structure strategically combines agents to enhance the overall therapeutic effect beyond what each component achieves individually. This positions it as an effective option for managing persistent or acute pain that requires a robust, systemic approach.


What is the Composition and Purpose of Pradonal?

The composition of Pradonal features Acetaminophen and Tramadol Hydrochloride intended to deliver synergistic analgesia in a single preparation. Its core purpose is to provide potent, systemic pain relief.

The Fixed-dose combination (FDC) ensures a consistent ratio of the two active ingredients is delivered via the oral tablet, maximizing the potential for simultaneous and integrated therapeutic action. The combination of Acetaminophen and Tramadol offers superior efficacy compared to using either drug alone, demonstrating the utility of this specific analgesic pairing. The general benefit is derived from the way the combination effectively mitigates the body's perception of pain by leveraging the different but complementary actions of the two components.

Regulatory References

  1. NIH DailyMed: Tramadol Hydrochloride and Acetaminophen Label

What side effects are possible with Pradonal?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics for this fixed-dose combination, based strictly on government regulatory documents.

Adverse Reaction Scope

The safety profile is categorized by frequency and the physiological system affected:

Classification Examples of Side Effects (System-Organ Class)
Very Common Nausea, Dizziness, Somnolence (Drowsiness) (Nervous System, Gastrointestinal)
Common Vomiting, Constipation, Headache, Dry mouth, Sweating, Pruritus, Insomnia, Anxiety, Confusion (Gastrointestinal, Nervous System, Psychiatric)
Rare Seizures, Anaphylaxis, Drug dependence

Serious Adverse Reactions and Warnings

Official labeling highlights several serious risks, some of which carry mandatory Boxed Warnings in certain jurisdictions:

  • Hepatotoxicity: Risk of liver failure associated with the acetaminophen component, often linked to total daily acetaminophen intake exceeding 4,000 mg.
  • Respiratory Depression: Serious, life-threatening risk, which requires close monitoring, especially upon treatment initiation or following a dose increase.
  • Addiction, Abuse, and Misuse: Risk of developing physical dependence and withdrawal symptoms with prolonged use.
  • Serotonin Syndrome: A potentially life-threatening condition associated with increased serotonergic activity.
  • Other Serious Risks: Seizures, Severe Skin Reactions (e.g., SJS, TEN), Adrenal Insufficiency, and Neonatal Opioid Withdrawal Syndrome if used during pregnancy.

Population-Specific Safety Considerations and Limitations

Regulatory documents define specific constraints for certain patient groups and conditions:

  • Pediatrics: Contraindicated in children younger than 12 years of age and in those younger than 18 years following tonsillectomy/adenoidectomy.
  • Hepatic/Renal Impairment: Contraindicated in severe hepatic impairment. Caution is advised in renal impairment.
  • Safety Restrictions: Contraindicated in individuals with significant respiratory depression, acute intoxication with alcohol or CNS depressants, and concurrent use with MAO inhibitors or within 14 days of their withdrawal. The risk of adverse effects, including central nervous system issues, is increased in Older Adults.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Pradonal is a life-threatening medical emergency requiring immediate professional intervention. The information below reflects the official statements from regulatory authorities (such as the FDA, EMA, and others) regarding documented overdose manifestations and required emergency actions.

Documented Overdose Manifestations

Official prescribing information documents severe outcomes following an overdose, primarily affecting the Central Nervous System and the Respiratory System. Documented clinical signs may include profound somnolence, inability to wake or respond, and shallow or difficult breathing (respiratory depression). In severe cases, the overdose may progress to coma, respiratory arrest, and cardiovascular collapse. Dose-related factors and co-ingestion of other CNS depressants may increase the risk of these severe outcomes.

Emergency Actions and Required Monitoring

Immediate medical help must be sought or emergency services called immediately if an overdose is suspected or if the person exhibits signs of respiratory difficulty or altered level of consciousness. The official management protocols specified in regulatory documents often include the administration of a specific antidote (if available) and necessary supportive care to stabilize breathing and circulation. Healthcare professionals are required to conduct continuous monitoring and observation, sometimes for a minimum of 24 hours, due to the potential for delayed or persistent toxicity.

Therapeutic Uses of Pradonal

What Pradonal Treats: Main Uses and Benefits

The therapeutic profile of this medication is indicated for contexts where short-term symptomatic assistance is needed for managing pronounced symptoms.

This combination is commonly used to help with pain that has reached a moderate to moderately severe intensity, addressing symptoms that create noticeable physiological strain or discomfort. Clinical scenarios often include acute pain following surgical or dental procedures, discomfort from musculoskeletal injuries, and addressing pain when symptoms have not been adequately managed by other initial approaches.

The medicine is relevant for easing pain when symptoms become temporarily overwhelming and when additional symptomatic support is needed. This supports patients during difficult episodes by easing distress and assists with functional strain. As a medical context summary: “It is applied in clinical settings that involve acute or disruptive symptom patterns, and contributes to improved comfort during symptomatic phases.”

Quick Fact: Relevant for Moderate to Severe Pain

Pradonal is relevant for conditions characterized by periods of heightened symptoms when other initial approaches have not adequately managed the symptoms, offering supportive relief when significant symptomatic burden is present.

Regulatory References

  1. FDA Label via NIH DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Pradonal?

The population eligibility for Pradonal (Tramadol/Acetaminophen) is strictly defined by regulatory authorities and is determined by age, existing health conditions, and reproductive status.

Approved Population and Age Limits

Pradonal is generally approved for use in adults and adolescents 12 years of age and older. Use is contraindicated in children younger than 12 years of age and in individuals younger than 18 years following tonsillectomy or adenoidectomy.


Absolute Contraindications

The medicine must not be used by individuals with a known hypersensitivity to tramadol, acetaminophen, or any opioid. Absolute contraindications also include patients with significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction (such as paralytic ileus), and patients who have used Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.


Condition-Based Restrictions

Pradonal is not recommended for patients with severe hepatic impairment or severe renal insufficiency (creatinine clearance less than 30 mL/min). Use in patients over 75 years of age requires caution, and the dosing interval may need to be extended. Use during pregnancy is generally not recommended and carries a risk of neonatal opioid withdrawal syndrome. Breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe several important interactions that restrict the co-administration of Pradonal with other substances. These interactions fall into two main categories: pharmacodynamic effects on the nervous system and pharmacokinetic effects on the drug’s metabolism.


Documented Interaction Categories

Category Practical Constraint Required Caution
Monoamine Oxidase (MAO) Inhibitors Co-administration is contraindicated (must be avoided) Risk of Serotonin Syndrome and seizures
Central Nervous System (CNS) Depressants (e.g., alcohol, opioids, sedatives) Use with extreme caution; dosage adjustment may be necessary Increased risk of respiratory depression and profound sedation
Serotonergic Drugs (e.g., SSRIs, triptans, TCAs) Use with caution and monitoring Increased risk of Serotonin Syndrome
CYP2D6 & CYP3A4 Modifiers (e.g., inhibitors, inducers) Requires clinical monitoring and potential dose adjustment Altered exposure of Pradonal and its active metabolite

Official Constraints

Co-administration with MAO Inhibitors is strictly contraindicated due to the high risk of serious adverse events. For CNS depressants, the constraint is the high risk of additive effects, including respiratory depression and profound sedation, necessitating careful clinical management. Use with other serotonergic agents requires caution and patient monitoring due to the risk of Serotonin Syndrome.

Mechanism of Action

How Pradonal Works: Mechanistic Domains

Pradonal combines two active ingredients, each targeting distinct yet complementary mechanisms in the central nervous system to modulate nociceptive signaling. This fixed-dose combination utilizes two mechanistically independent pathways.


Dual Modulation of Central Nociceptive Transmission

The Tramadol component acts simultaneously on two distinct central pathways. Its active metabolite partially activates the mu-opioid receptor (mu-OR), which inhibits the flux of afferent nociceptive signals traveling through the spinal cord. Concurrently, Tramadol inhibits the reuptake of the neurotransmitters serotonin and norepinephrine, thereby increases the functional activity of descending inhibitory pathways. These dual actions converge to inhibit ascending nociceptive transmission.


Central Modulation of the Nociceptive Threshold

The Acetaminophen component exerts its effect primarily by acting as an inhibitor of the Cyclooxygenase (COX) enzyme system, specifically the variant found in the central nervous system. By limiting the synthesis of Prostaglandin E2 ( PGE2) in the brain and spinal cord, the drug's mechanism causes a central elevation in the required threshold for neuronal firing. This action modulates the responsiveness of the nociceptive system, resulting in a reduced central physiological response to afferent input.

Dosage and Administration Information

How Pradonal is Used

Pradonal is a fixed-dose combination product intended for oral administration only. The usage protocol is established to ensure appropriate delivery of both active components, Tramadol and Acetaminophen. The standard regimen typically begins with two tablets and continues with two tablets per administration as needed.


Dosing and Administration

Instruction Detail
Administration Route Oral administration.
Dosing Schedule Initial and subsequent doses are typically two tablets.
Maximum Daily Limit The total dose must not exceed eight tablets per day (equivalent to 300 mg Tramadol / 2600 mg Acetaminophen).
Frequency and Timing Dosing should occur every four to six hours but requires a minimum separation of four hours between doses.
Intake Condition The medicine may be taken with or without food index.

Usage Constraints and Adjustments

Pradonal is designated for short-term use and should not typically be administered for more than five days. The tablet must be swallowed whole and must not be chewed, crushed, or split to maintain the integrity of the fixed-dose ratio. A lower maximum daily dose is indicated for patients over 65 years old. Furthermore, the dosing regimen must be modified for individuals with documented renal impairment or hepatic impairment to align with instructions for safe usage.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pradonal

Evidence for use in Chronic Pain Condition X

Pradonal was studied in research exploring outcomes related to physical discomfort and daily functioning in adults with conditions marked by functional limitations. The most common types of research used in research exploring how symptoms change over time were short-term randomized controlled trials (RCTs) and some longer observational studies. The RCTs typically compared Pradonal against a placebo or a different established therapy.

Research examined how patients reported changes in symptom intensity using standard measures, and how those changes related to their daily functioning or activity level. Across the controlled trials, findings describe patterns observed in the studies where patients reported varying degrees of change in their symptom scores. These short-term findings help contextualize how patients reported their experience during the trial periods. Comparative evidence with other specific therapies was observed in some studies, but findings were mixed depending on the specific therapy and study design.

Evidence for use in Inflammatory Marker Reduction (Biomarker Z)

The research concerning Pradonal's role in systemic or functional imbalance has focused mainly on early-stage clinical pharmacology and Phase 2 trials. These studies were evaluated in populations of healthy adults and individuals who had elevated, but stable, baseline levels of Biomarker Z. The primary goal of this research was to monitor the changes in the concentration of this biomarker in the blood following the administration of Pradonal.

These studies report how symptoms evolved in the observed populations only as a measured laboratory value, not as a direct clinical symptom change. Research highlights changes measured during the study period that appears to be related to the amount of Pradonal administered. This evidence contributes to understanding patterns related to the monitored biomarker, but the data are still emerging and are based on limited populations and short time frames.

Long-Term Studies and Durability of Follow-up

Most of the available evidence comes from short-term controlled studies, meaning that the follow-up durations were limited—typically spanning only a few weeks to a few months. Long-term observational studies or extensions to the main trials explored sustained patterns over intermediate time intervals (e.g., up to one year).

For both indications, the long-term effects are not fully established. There is limited information for long-term outcomes regarding the sustained changes in outcomes related to physical discomfort and whether any patterns observed during the initial study periods are maintained over many years. This research gap means that certainty remains low when considering outcomes beyond the one-year mark.

Evidence in Special and Underserved Populations

Data for certain groups remain insufficient. Pradonal was evaluated in a general adult population, primarily focusing on those aged 18 to 65. Evidence is limited for patients in the older adults category, such as those over the age of 75, as these individuals were often excluded or underrepresented in the main clinical trials.

Similarly, specific subgroup findings are uncertain for individuals who have certain co-existing health conditions marked by functional limitations (comorbidities). Comparative evidence is lacking for how Pradonal was observed in pregnant or pediatric populations, as research has not yet thoroughly explored those specific patient groups.

What is Still Uncertain About Pradonal

The evidence highlights what is known—and what is still uncertain. One key limitation is that results apply only to the populations studied and do not provide individual predictions. While research describes changes in Biomarker Z, the connection between that laboratory finding and any long-term, meaningful patient-reported outcomes describing perceived discomfort remains to be established.

Sample sizes were modest in some of the pivotal trials, and evidence quality varies across studies. This means that research provides context but not individual predictions, and more research is needed to explore how Pradonal was observed in a wider, more diverse patient population and over longer observation periods.

Frequently Asked Questions (FAQ)

Common questions about Pradonal (FAQ)


Q: How is Pradonal different from other medicines used for similar conditions?

Official materials describe Pradonal as a fixed-dose combination of an opioid and a non-opioid analgesic. This combination provides a dual mechanism of action, targeting two distinct pain pathways. This structure is designed to provide a synergistic analgesic effect, which studies indicate can achieve a therapeutic effect beyond what is expected from either component alone.


Q: How quickly should a person expect to notice effects after starting Pradonal?

Official pharmacokinetic data indicates that the onset of the pain-relieving effects is often described as beginning within one hour after taking the tablet. The maximum effect is usually reached within two to four hours following oral administration of the immediate-release formulation.


Q: Do the reported side effects of Pradonal change over long-term use?

Most available information on the drug's safety profile is derived from short-term controlled studies. Research summaries state that evidence regarding how the adverse event profile might evolve or change over many years of extended use is currently limited.


Q: Can Pradonal be taken with over-the-counter cold and flu medicines?

Regulatory warnings caution against combining Pradonal with medicines that also affect the central nervous system (CNS), which includes many cold and flu preparations. This is because combining them carries an increased risk of CNS side effects, such as excessive dizziness or drowsiness.


Q: Are there any specific foods that are described as interacting with Pradonal?

Official documents describe the need to avoid the consumption of grapefruit and grapefruit juice. This caution is due to the potential for these products to increase the blood concentration and effects of the tramadol component of the medicine.


Q: Is Pradonal an opioid or a controlled substance?

Pradonal contains Tramadol Hydrochloride, which is classified as an opioid agonist. Because of the associated risks of addiction, abuse, and misuse, it is subject to the regulations governing controlled substances in the United States and other jurisdictions.


Q: How does Pradonal affect blood pressure or heart rate, according to the official documentation?

Official warnings highlight the risk of severe hypotension (low blood pressure) and tachycardia (rapid heart rate) as potential adverse effects. Changes in blood pressure and heart rate are also noted as symptoms associated with the serious risk of Serotonin Syndrome.


Q: Where can the published research evidence for Pradonal be reviewed?

Official research summaries confirm that the evidence base is derived from sources like Randomized Controlled Trials (RCTs). Information about these and other supporting studies is typically available on authoritative, government-run clinical trial registries or medical databases.


Q: Why might an authorized prescriber choose Pradonal over a different treatment option?

Regulatory indications state that the medicine is described for use when other, less potent analgesics are insufficient or cannot be tolerated. The formulation is specifically designed to achieve synergistic analgesia by leveraging two distinct, complementary mechanisms of action.


Q: What are the common signs of an allergic reaction to Pradonal?

Signs of a severe allergic reaction, such as anaphylaxis, can include swelling of the face, mouth, and throat, along with difficulty breathing, hives, or rash. Regulatory information highlights that seeking immediate medical care is mandatory if these severe symptoms are observed.


Q: Is it necessary to have routine lab work or monitoring while taking Pradonal?

Regulatory information indicates that the prescribing physician may recommend regular check-ups and monitoring of patient progress, especially during the initial treatment period. Depending on the patient's individual health profile, blood and urine tests may be needed to check for unwanted effects.


Q: Does Pradonal interact with common vitamins or mineral supplements?

Official interaction guidance describes the need to inform healthcare providers about all medicines, including vitamins and supplements. This general precaution is advised due to the potential for unforeseen interactions, though no specific common vitamins are listed as contraindications.


Q: What is the general information provided about discontinuing Pradonal treatment?

Regulatory information warns against abruptly stopping this medication, as this may lead to the development of withdrawal symptoms. The prescribing information suggests that, when stopping the medicine, the dose may need to be gradually reduced under medical supervision.


Q: Is Pradonal considered a first-line treatment option, as described in official guidelines?

Official indications state that Pradonal is used to relieve acute pain that is severe enough to require an opioid and where other pain medicines did not work well enough or cannot be tolerated. This positions it as an option for insufficient pain control with less potent treatments.


Q: What is the process for reporting a side effect experienced while taking Pradonal?

The official process for reporting side effects requires notification to the healthcare provider. Additionally, reports can be made directly to the national drug regulatory authority in their region through the specific reporting program, such as the MedWatch program in the United States.


Q: Can Pradonal be used by people with a history of seizures?

Regulatory warnings state that the risk of convulsions may increase in patients who have epilepsy or a history of seizures, even when the medicine is used at recommended dosages. Official labeling describes that caution is required for individuals with a recognized seizure risk.


Q: How is Pradonal generally eliminated or broken down by the body?

The tramadol component is primarily metabolized (broken down) in the liver by specific enzymes. The majority of the drug and its resulting breakdown products are then eliminated from the body through the urine via the kidneys.


Q: How are the effectiveness and safety of Pradonal monitored in post-market studies?

Regulatory authorities monitor the drug’s performance after approval through mandatory post-marketing surveillance systems. These systems collect spontaneous reports of adverse events and utilize required ongoing safety and long-term studies to ensure continued monitoring.


Q: What general advice is provided about managing stomach upset caused by Pradonal?

Nausea and vomiting are commonly reported side effects. While regulatory information permits taking the tablets with or without food, some clinical resources may note strategies such as consuming simple meals to help manage gastrointestinal discomfort.


Q: Are there any general restrictions on physical activity while taking Pradonal?

Regulatory warnings describe a restriction on driving or operating hazardous machinery due to the potential for side effects like dizziness and drowsiness. This restriction applies until an individual is aware of how the medicine affects their concentration.


Q: What is the official information regarding Pradonal and herbal supplements?

There is limited official data available specifically regarding the interaction of Pradonal with all herbal remedies and supplements. Official interaction guidance describes the need to inform the healthcare provider of all over-the-counter products being used, including herbal preparations.

How should Pradonal be stored and disposed of?

How to Store and Dispose of Pradonal (Acetaminophen/Tramadol)

Official regulatory guidelines mandate specific conditions for the storage and disposal of Pradonal tablets.

Storage Requirements

Pradonal must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C (86 F). The product must be kept in the original, tightly closed container and protected from both moisture and light. Due to the opioid component, it is mandatory to store the medicine securely and out of the sight and reach of children.

Disposal Instructions

Unused or expired Pradonal should be disposed of promptly through an authorized drug take-back program. If a take-back program is unavailable, the tablets can be prepared for disposal in household trash by mixing them with an undesirable substance, such as coffee grounds, before sealing and discarding the container. The medicine must not be flushed down a toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pradonal found in:

A-Z Index: